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Purpose: To evaluate the dosimetric performance and planning/delivery efficiency of a
dual-layer MLC system for treating multiple brain metastases with a single isocenter.
Materials and Methods: 10 patients each with 6–10 targets with volumes from 0.11
to 8.57 cc, and prescription doses from 15 to 24Gy, were retrospectively studied.
Halcyon has only coplanar delivery mode. Halcyon V1 MLC modulates only with the
lower layer at 1 cm resolution, whereas V2 MLC modulates with both layers at an
effective resolution of 0.5 cm. For each patient five plans were compared varying MLC
and beam arrangements: the clinical plan using multi-aperture dynamic conformal arc
(DCA) and non-coplanar arcs, Halcyon-V1 using coplanar-VMAT, Halcyon-V2 using
coplanar-VMAT, HDMLC-0.25 cm using coplanar-VMAT, and HDMLC-0.25 cm using
non-coplanar-VMAT. All same-case plans were generated following the same planning
protocol and normalization. Conformity index (CI), gradient index (GI), V12Gy, V6Gy,
V3Gy, and brain mean dose were compared.
Results: All VMAT plans met clinical constraints for critical structures. For targets
with diameter <1 cm, Halcyon plans showed inferior CI among all techniques. For
targets with diameter >1 cm, Halcyon VMAT plans had CI similar to non-coplanar
VMAT plans, and better than non-coplanar clinical DCA plans. For GI, Halcyon
MLC plans performed similarly to coplanar HDMLC plans and inferiorly compared to
non-coplanar HDMLC plans. All coplanar VMAT plans (Halcyon MLC and HDMLC)
and clinical DCA plans had similar V12Gy, but were inferior compared to non-coplanar
VMAT plans. Halcyon plans had slightly reduced V3Gy and mean brain dose
compared to HDMLC plans. The difference between Halcyon V1 and V2 is only
significant in CI of tumors less than 1cm in diameter. Halcyon plans required
longer optimization than Truebeam VMAT plans, but had similar delivery efficiency.
Li et al. Performance of Halcyon MLC on SRS Cases
Conclusion: For targets with diameter >1 cm, Halcyon’s dual-layer stacked and
staggered MLC is capable of producing similar dose conformity compared to HDMLC
while reducing low dose spill to normal brain tissue. GI and V12Gy of Halcyon MLC plans
were, in general, inferior to non-coplanar DCA or VMAT plans using HDMLC, likely due
to coplanar geometry and wider MLC leaves. HDMLC maintained its advantage in CI for
smaller targets with diameter <1 cm.
Keywords: halcyon, stereotactic radiosurgery (SRS), multi-leaf collimator (MLC), single-isocenter multi-target,
truebeam, brain metastase
INTRODUCTION
Stereotactic radiosurgery (SRS) has gained substantial
popularity in the radiation oncology community, especially
in smaller clinics. It has become a standard and effective way to
manage brain metastases for cancer patients (1–4). There have
been accumulated studies indicating that, for cancer patients
with metastatic brain tumors, SRS provides effective and safe
treatment compared to whole-brain radiation therapy (WBRT)
alone, both as a monotherapy and combined with WBRT
(5, 6). In addition, it has been reported that the deterioration of
neurocognitive function following SRS is much less pronounced
than WBRT, and therefore improves the quality of life for cancer
survivors (5–7). Additional benefits of using SRS to control brain
metastasis include substantial time and resource savings for the
clinical care team, as well as preserving options of re-irradiation
either to the remaining part of the brain or another part of the
body.
The recent development of high-precision treatment delivery
systems and image guidance expanded SRS treatment to
linac-based radiation therapy centers. The use of volumetric-
modulated arc therapy (VMAT) and high-definition multileaf
collimators (HDMLC) enabled precise control of beam apertures
to create conformal dose to the target while maintaining fast dose
fall-off outside the target.
More recently, a new type of straight-through linac has been
introduced by Varian Medical Systems (Palo Alto, CA). The
new linac, named HalyconTM, offers improved mechanical design
and treatment workflow. The gantry rotation is 4 times faster
than a typical C-arm linac, such as the Truebeam R© (Varian
Medical Systems, Palo Alto, CA), with a ring-shaped enclosure
which minimizes the possibility of collision. In addition, a new
dual-layer stacked and staggered MLC design was introduced
to this delivery system for a jaw-less configuration. This new
type of MLC offers leaf speeds that are 2 times faster than
traditional MLCs on Varian linacs, reduced leakage to ∼0.05%
(due to stacked layers and larger leaf height), and an improved
penumbra with smaller dosimetric leaf gap (DLG) of 0.1mm.
This improved design, coupled with 6FFF energy, makes it a
potentially favorable beam-shaping device for cranial treatment.
Halcyon version 1 (V1) only uses lower MLC layer as beam-
shaper and to modulate intensity/apertures while the upper layer
MLC “ride along” the lower layer to provide additional shielding,
similar to back-up jaws. So the modulation resolution of Halcyon
V1 is limited at 1 cm perpendicular to the MLC traveling
direction. Halcyon version 2 (V2) enables the upper layer to be
used for beam shaping along with the lower layer, effectively
producing 0.5 cm theoretical modulation resolution due to the
0.5 cm staggered design. Some physical design and functionality
differences between Halcyon MLC and previous HD-120 MLC
and Millenium-120 MLCs are illustrated in Figure 1, as well as
the difference between Halcyon version 1 and version 2.
The current limitations of Halcyon MLC design compared to
the Truebeam platform for the purpose of SRS are 2-fold. First,
the MLC leaves are 1 cm wide with 0.5 cm offset between the
upper and lower layers. This limits the theoretical modulation
resolution to 0.5 cm when both layers are used. Compared to
the widely accepted MLC design for SRS applications, which
has 0.25 cm leaf width, the wider MLC leaves could lead to
inferior dosimetric performance for small lesions. Second, the
current Halcyon design does not allow couch rotation and,
therefore, cannot generate non-coplanar beam arrangements
that are typically used in SRS applications. This potentially has
negative impact on dosimetry as well.
Nevertheless, Halcyon MLC exhibits lower leakage and a
smaller penumbra, which may provide some benefits for SRS.
Given the improvements and limitations of this new delivery
system, it is important to understand how this system performs
compared with other linac-based delivery configurations for
multiple brain metastasis treatment. Due to the increasing
popularity of performing SRS treatments at community centers,
where the Halcyon platform was primarily designed for,
we designed this comparative study. The study provides a
benchmark dosimetry evaluation comparing Halcyon treatment
plans to current standard treatment techniques for multiple brain
metastasis with a single isocenter.
METHODS AND MATERIALS
With IRB approval, 10 patients with multiple brain metastases
treated with a single isocenter on a C-arm linac were
retrospectively studied. The number of tumors treated for
each patient in one session ranges from 6 to 10. Tumor size
distribution for each patient is shown in Figure 2. For most
patients there is at least one larger target receiving 15Gy−18Gy
Rx, and several small targets receiving Rx between 21 and 24Gy,
representing a wide distribution of target sizes and Rx levels that
we commonly see in clinic.
Clinical treatment plans for these patients were developed
using a single isocenter multi-aperture dynamic conformal arc
technique implemented in the Brainlab ElementsTM treatment
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FIGURE 1 | (Left) MLC Design comparison of current dual-layer Halcyon MLC (brown) vs. 0.25 cm wide HD-120 MLC (Green) and 0.5 cm wide Millenium-120 MLC
(Red) showing increased leaf thickness and rounding radius. (Right) Different between Halcyon MLC version 1 and version 2. Halcyon V2 enables the upper layer to
be used for beam shaping, effectively producing 0.5 cm modulation resolution.
FIGURE 2 | Distributions of tumor sizes for all 10 patients included in this study.
planning system. Additional comparative treatment plans were
generated in EclipseTM treatment planning system using three
different VMAT techniques: non-coplanar VMAT using 0.25 cm
Truebeam HD-MLC, coplanar VMAT using 0.25 cm Truebeam
HD-MLC, and Halcyon MLC. The reason that coplanar
Truebeam HD-MLC was included here was not due to clinical
reasons, but to provide a similar beam arrangement as in
Halcyon. Figure 3 shows the study design diagram and different
types of MLCs.
All treatment plans were developed with 6MV flattening-
filter-free (6XFFF) energy and maximal dose rate for the type
of linac: 1,400 MU/min for Truebeam, and 800 MU/min
for Halcyon. Beam arrangement differs from technique to
technique. For the original treatment plan developed using
Brainlab ElementsTM system, 5–9 arcs with 6MV flattened (6X)
energy were used depending on the preconfigured templates.
All arcs are dynamic conformal arcs in nature, i.e., the MLC
only conforms to targets at all angles and are not used for
modulation. All VMAT treatment plans followed one standard
planning strategy reported by Clarks et al. (8), with the
exception of beam arrangement. Isocenters were all placed
automatically by the TPS at the center of mass of all targets
combined. Non-coplanar VMAT plans used a 4-arc technique
with 1 full (360◦) arc at 0◦ couch rotation and 3 non-coplanar
half (180◦) arcs at couch rotation of 45◦, 135◦, and 270◦.
Coplanar VMAT plans used 2–3 arcs, depending on the number
of targets, and maintained consistency across Truebeam and
Halcyon plans. For all treatment plans, Photo OptimizerTM
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FIGURE 3 | Study design flowchart.
v15 was used for optimization and the Analytical Anisotropic
Algorithm (AAA) v15 with calculation grid set to 1mm was
used for dose calculation. The optimization process is the same
between Truebeam and Halcyon treatment plans. All plans were
normalized so that the minimal coverage by the prescription dose
to any targets is at or above 99% of target volume (V100%≥ 99%).
Key dosimetric parameters were compared across treatment
plans. The comparison was performed in two parts: per-
target dosimetry comparison that included conformity index
(CI) and gradient index (GI) for each target, and per-plan
dosimetry evaluation on total brain V12Gy, V6Gy, V3Gy, and
mean dose (Dmean) to normal brain for the total treatment.
V12Gy has been used as a key factor associated with radiation-
induced necrosis (9, 10), and is therefore an important factor to
assess. Per target paired comparisons across different planning
and delivery platforms were conducted within two groups
defined by equivalent target diameter >1 and ≤ 1cm. CI
was calculated following the ICRU 62 definition (11): CI =
VRx/VPTV, where VRx is volume of the prescription dose and
VPTV is volume of the PTV. GI was calculated as defined
by Paddick and Lippitz (12): GI = V50%Rx/V100%Rx, where
V50%Rx is the volume of the 50% isodose line and V100%Rx
is the volume of the 100% isodose line. Since all targets
were normalized to have prescription dose covering at least
99% of the target volume, target coverage is already ensured.
Therefore, ICRU CI was used to highlight excessive dose
outside the target following Clarks et al. In plans where
a different prescription was used for different targets based
on the size, GI was calculated based on the corresponding
prescription dose to each particular target. Homogeneity index
(HI), defined as Dmax/Rx, was documented but not included
in paired comparison. This is because maximal dose (Dmax)
was not constrained during optimization following guidelines by
Clarks et al. and our institutional practice, therefore HI does
not directly reflect each system’s ability to achieve planning
objectives. Wilcoxon signed rank test (13–15) was used as a non-
parametric test for paired data based on differences between
paired dosimetric parameters of plans generated by different
planning and delivery platforms. The test is based on ranks
of the difference values between paired samples, and, unlike
t-test, does not assume any distribution characteristics of the
underlying population. Statistical significance level was set at
p < 0.05.
To assess optimization and delivery efficiency across multiple
planning techniques, optimization time was recorded for 5
patients, and delivery efficiency were assessed for all 10
patients by comparing total MU and estimated delivery time.
Because DCA plans do not involve VMAT optimization, it
was excluded from the optimization efficiency comparison.
Estimated delivery time was calculated by considering the
actual machine limits (dose rate, gantry rotation, MLC speed).
Because of the high MU nature of all SRS plans (>3,000
MU per arc), the limiting factor for delivery speed is found
to be machine dose rate for all cases. Therefore, estimated
delivery time was calculated from total MU by using machine-
specific maximal dose rate of 1,400 MU/min for HDMLC
plans, 800 MU/min for Halcyon plans, and 600 MU/min for
DCA plans, plus 1min per non-zero couch rotation angles
to allow for setup and verification process for each non-
coplanar arc.
RESULTS
Per Target Dosimetry Analysis
Figure 4 shows the CI comparison across multiple planning
and delivery techniques, fitted to the equivalent target diameter
calculated by treating the targets as spherical. According to
radiosurgery quality assurance guidelines established by RTOG,
a CI above 2.0 is considered as a minor deviation from the
guideline and a CI of 2.5 and above is considered as a major
deviation from the guideline (16). From the data shown in
Figure 4, all of the targets had CIs <2.5 with the majority of the
targets’ CI below 2.0. This indicates that, from the conformity
point of view, all techniques and MLC designs satisfied the
clinically acceptable requirement.
For targets <1 cm in diameter, non-coplanar plans in general
achieved better conformity compared to coplanar plans. Within
coplanar plans, Halcyon V2MLC showed improved CIs for small
targets compared to V1 MLC. V2 MLC also performed very
similarly compared to CIs achieved with HD MLC, which had
twice finer modulation resolution perpendicular to leaf travel
(0.25 cm for HD MLC vs. 0.5 cm for Halcyon V2 MLC). For
targets with diameter larger than 1 cm, all VMAT plans, including
Halcyon V1 MLC and V2 MLC plans, exhibited superior CI
compared to clinical DCA plans. The CI performance difference
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FIGURE 4 | Comparison of conformity index (CI) as a function of target equivalent diameters for five planning and delivery techniques. Dots are the actual CI for an
individual target. Solid lines are fitting lines using spline model and the shaded areas are 95% confidence interval of fit.
among all VMAT plans are not significantly different for targets
larger than 1 cm.
Figure 5 compares GI as a function of target equivalent
diameter across 5 delivery and planning techniques. Seven targets
(35 data points), out of 80, were not included in the GI fitting
graph due to the bridging of their 50% isodose volume with
another nearby target. When a target’s 50% isodose volume
bridges with another target’s, the V50% no longer describes
dose fall off around one single target, and therefore cannot
characterize the MLC system. However, this does not mean that
the overlap region is neglected. In fact, the overlap region and its
dosimetric impact is fully evaluated in the V12Gy analysis later.
Overall, non-coplanar techniques achieved lower GI compared to
coplanar solutions. Comparison across coplanar plans suggested
that Halcyon MLC in general had inferior GI for targets smaller
than 1 cm in diameter, but comparable GI for targets larger than
1 cm in diameter when compared to HDMLC.
Figure 6 visualizes a paired CI and GI comparison with
respect to clinical baseline plan. Since we used clinical
non-coplanar DCA plans with HDMLC as baseline, in this
comparison all VMAT plans’ CI and GI are presented relative to
the DCA plans’ CI and GI in terms of absolute difference in value;
i.e.,CIVMAT−CIDCA andGIVMAT−GIDCA. Based on observations
in Figures 4, 5, the boxplots are also divided into two sections for
targets with diameter larger (35 targets) or smaller (45 targets)
than 1 cm.
The CI and GI differences between techniques for each target
are also analyzed and summarized in Table 1, with the targets
separated based on their diameter (>1 or <1cm). For each
case, the CI or GI for the corresponding technique located in
the first column of each table is subtracted from the CI or
GI for the corresponding technique located in the top row,
respectively. Themean, standard deviation, andWilcoxon Signed
Rank test results of all per-case CI or GI differences are then
summarized and shown in the table cell. Positive mean values in
the table cells indicate that the corresponding technique in the
top row produced on average a higher CI or GI compared to
the corresponding technique in the first column on the left; and
negative values indicate the opposite. Wilcoxon Signed Rank test
was used to determine the statistical significance in the difference
and the p-values are reported alongside the difference. Values that
are statistically significant (p < 0.05) are bolded for clarity.
Overall, non-coplanar VMAT plans exhibited superior CI and
GI, which can be seen in Figures 4–6, as well as in Table 1 where
all mean CI/GI differences relative to non-coplanar VMAT plan
are positive (3rd row in each sub-table). Regardless of tumor size,
all coplanar techniques (both Halcyon MLC and HDMLC) had
inferior GI compared to DCA plans (positive mean values in
2nd row, column 3–5 of Sub-Tables 1C,D). For small targets with
diameter <1cm, Halcyon V1 and V2 plans exhibited statistically
significant increase in CI and GI (last two columns in Sub-
Tables 1A,C) compared to all HDMLC plans including DCA and
VMAT. Compared to Halcyon V1, Halcyon V2 improved CI for
small targets but not GI (lower-right cell in Sub-Tables 1A,B). For
targets with diameter> 1 cm, all VMAT plans, includingHalcyon
V1 and V2, achieved significantly better CI than DCA plans as
shown by negative mean values in the 2nd row of Sub-Table
1B. Halcyon V2 MLC using coplanar beams achieved similar
CI compared to non-coplanar VMAT with HDMLC but inferior
GI (3rd row last column in Sub-Table 1B,D). The differences in
GI for large tumors between all coplanar techniques, including
Halcyon V1, V2, and HDMLC in coplanar setting, were not
significant (row 4–5 column 4–5 in Sub-Table 1D).
The mean homogeneity index (HI) for each technique (with
95% confidence interval) is as follows: 1.26 (1.23–1.30) for non-
coplanar DCA, 1.41 (1.38–1.44) for Halcyon V1, 1.42 (1.38–1.45)
for Halcyon V2, 1.40 (1.37–1.43) for non-coplanar VMAT with
HDMLC, and 1.53 (1.49, 1.56) for coplanar VMATwithHDMLC.
These results are consistent with findings published by other
groups (8) and are well below the published HI of GammaKnife-
based SRS (1). It should be noted that these HI statistics were
based on SRS plans optimized without maximal dose objectives
and could substantially change if maximal dose objectives were
used during optimization.
Per Patient Dosimetry Analysis
On a per-patient level, clinicians care about the total excessive
dose delivered to the normal brain tissue, as well as key organs at
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FIGURE 5 | Comparison of gradient index (GI) variation as a function of target equivalent diameters for five planning and delivery techniques. Dots are the actual GI for
an individual target. Solid lines are fitting lines using spline model and shaded areas are 95% confidence interval of fit. Only GIs <15 are included in the graph to avoid
data skewing due to bridging 50% isodose lines.
FIGURE 6 | Matched pair comparison of CI and GI between each VMAT technique and the corresponding clinical DCA plans separating cases into two groups by
equivalent target diameter. N means target diameter is ≤1 cm and Y means target diameter is >1 cm. Wilcoxon signed rank test was used to assess statistical
significance of the difference between VMAT plan’s CI/GI and those of the clinical DCA plans.
risks. Therefore, in the following section, the normal tissue dose
matrices were examined.
The dose spillage to normal brain tissue at multiple dose
levels are compared in Figure 7. To better visualize a wide
range of volume parameters, the vertical axis is displayed in log
scale. V12Gy is of particular interest because of its correlation
to radionecrosis following SRS treatment. Non-coplanar VMAT
with HD MLC outperformed all other techniques with a
significantly lower V12Gy (p = 0.002 for paired comparison
with all other groups). However, both Halcyon MLC plans
performed very similar to non-coplanar DCA plans, and
slightly better than coplanar HD MLC plans. For V6Gy, both
non-coplanar techniques outperformed coplanar techniques;
however, V6Gy between Halcyon and HD MLCs were very
similar. Mean dose to Brain-GTV was found to be similar
for all techniques regardless of arc arrangement or MLC.
As an indicator of low dose spillage to brain tissue, V3Gy
comparison showed that Halcyon V2 offered improved low
dose volume to normal brain tissue compared to both coplanar
(p = 0.004) and non-coplanar (p = 0.01) plans using HD
MLC. Difference in V3Gy between DCA and Halcyon V2
VMAT plans was not significant (p = 0.557). These results
demonstrated the advantage of the low leakage MLC design in
Halcyon.
In addition to normal brain tissue, doses to several
critical organs-at-risk were also assessed according to their
dose constraints. The results are shown in Figure 8. All
VMAT plans met clinical constraints on OARs. No substantial
differences were observed across different MLC and planning
techniques.
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FIGURE 7 | Comparison of dose spillage to normal brain tissue from 5 different techniques. Parameters shown are V12Gy, V6Gy, and V3Gy in cc, and mean dose to
brain-GTV volume in cGy. Within each box there are 10 plans summarized.
FIGURE 8 | Maximal doses to key OARs compared in boxplots across all planning and delivery techniques. Thick dashed lines show the clinical constraints used.
Within each box there are 10 plans summarized. Dots indicate outliers defined by 1.5 interquartile range (IQR).
Optimization and Delivery Efficiency
Results for optimization and delivery efficiency were recorded
for five patients under the same calculation configuration.
Optimization times were similar across different treatment
planning strategies within both the Truebeam and Halcyon
platforms, but differed substantially between the two. Truebeam
optimization times ranged from 15 to 24min while Halcyon
optimization times ranged from 28 to 40min.
Delivery efficiency was assessed by total MU and estimated
delivery times of treatment plans were generated for the
different planning strategies. From Figure 9 it can be seen
that the total MU were similar across all VMAT techniques,
regardless of machine type or arc arrangement. No statistical
significance was found in any paired tests between VMAT
techniques. DCA plans had substantially lower MU than VMAT
plans, which is expected due to the absence of modulation.
The estimated delivery time showed that Halcyon plans
in general had higher delivery times than HDMLC plans.
This is mainly due to the maximal dose rate limit of 800
MU/min for the current Halcyon platform, compared to 1,400
MU/min for HDMLC with 6FFF energy on the Truebeam
platform.
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FIGURE 9 | Optimization and delivery efficiency comparison across different planning strategies. For optimization, only 5 patients were included and, because it does
not include VMAT optimization, DCA was omitted from the optimization time chart. For delivery efficiency, both total MU and estimated delivery time are shown.
Estimated delivery time was calculated using the dose rate and gantry rotation speed limits plus 1min per non-zero couch angle due to additional time required for
setup and verification.
DISCUSSIONS
In this study, the performance of the Halcyon dual layer stacked
and staggered MLC on small target dosimetry was quantified
in the context of single isocenter multi-target radiosurgery. The
purpose of this study was to explore the strengths and weaknesses
of this new MLC design when it comes to treating multiple
isolated small targets. We identified that size of the tumor
(>1 or <1 cm) played an important role in the performance
comparison study. When considering treating very small cranial
lesion, <1 cm, preference would be to treat them in a clinic
equipped with HDMLCs and non-coplanar delivery capabilities.
The results also demonstrated that Halcyon’s 1 cm-wide MLC,
with its staggered design, is capable of producing a conformity
index similar to that achieved by a much finer MLC (0.25 cm
width) for tumors >1 cm in diameter. It is worth noting that, for
these tumors, the Halcyon actually achieved better CI compared
to clinical plans generated using the DCA technique. For smaller
tumors with diameter <1 cm, the CIs achieved by using Halcyon
MLC were found to be inferior when compared to using HD
MLCs, but still met clinical constraints for the majority of cases.
GI analysis showed the Halcyon MLC was capable of achieving
similar GI compared to HDMLC in a coplanar setting for tumors
larger than 1 cm in diameter, but slightly inferior for smaller
tumors.
In both Figures 4, 5 there were targets outside 95%
confidence-of-fit region (color-shaded area). It should be noted
that this band only represents the uncertainty in the estimate
of the fitted line at different target diameters, and is not
a direct indication of the data distribution. One possible
explanation for the spread of these outliers is the low dose
interaction between different targets. If only one target is
treated, the CI/GI should mostly be determined by MLC
and planning techniques. However, when there are multiple
targets being treated at the same time, dose fall-off region
between nearby targets could overlap, either due to limited
blocking resolution of the MLC or the proximity of the two
targets. This could cause CI/GI being affected by parameters
other than the diameter of the target. The smaller the target,
the more likely this dose spillage could impact its CI/GI
calculation, therefore higher spread is seen in general for smaller
targets.
It should be noted that these results were based on using the
same optimization constraints across all platforms to standardize
the experiment condition and highlight potential differences
due to MLC and arc arrangement limitations. It is possible to
modify objectives for Halcyon platform to further improve some
dosimetric parameters while maintaining target coverage and
OAR doses. However, more stringent objectives are likely to
increase the level of modulation and, therefore, the total MU.
Multi-criteria optimization could be used to explore optimal
trade-off between target coverage, dose fall-off, OAR doses, and
delivery efficiencies.
One of the major limitations of the current Halcyon platform
design is the omission of a rotatable couch, i.e., without
yaw correction. This limitation could be the main reason for
Halcyon’s inferior GIs compared to clinical plans and non-
coplanar VMAT, because coplanar VMAT, even with finer HD
MLC, exhibited similarly inferior GIs. In addition, the MLC leaf
width could also be a contributor to the difference observed on
GI, as suggested by previous publications comparing leaves with
different width on SRS dosimetry (17). Detailed small field profile
analysis would also be helpful in understanding the Halcyon
MLC’s performance in terms of beam shaping and penumbra
region characteristics.
However, in a clinical setting, especially for multiple targets
scenario, total V12Gy should also be considered in addition
to individual GI when assessing dose fall-off (18). It has been
shown in the results section that, even with the limitation
of coplanar beam arrangement, Halcyon achieved similar total
V12Gy per plan as the clinical DCA plan. Figure 10 illustrates
a representative case where non-coplanar beam arrangements
exhibited better dose fall-off within the target plane in the
axial direction, but increased low dose spread to tissue located
between target planes. This, in part, reduced the advantage
of having non-coplanar beams, and could explain why non-
coplanar DCA plans had comparable V12Gy to coplanar
arrangements.
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FIGURE 10 | Illustration of dose fall-off characteristics across multiple different delivery techniques, both in and outside the target plane. Non-coplanar beam
arrangements in general have better dose fall-off in the target plane (top row), but bears more low dose spread to tissue between target planes (2nd row).
Another benefit using HalcyonMLCs was the reduced volume
of normal brain receiving low dose (3Gy) as well as lower
mean dose to the normal brain tissue, as shown in Figure 7.
This is likely due to the improved leakage characteristics of the
dual-layer MLC design (<0.1%) compared to traditional MLC
design (∼1%). For SRS treatment, very high cumulative monitor
units (6,000-10,000) are often delivered. This is especially true
for multi-target delivery, where the jaw has to be open to
encompass multiple targets while the majority of the jaw opening
is blocked by the MLCs. This makes the MLC transmission the
dominate factor on effecting normal tissue dose. Reduction from
1 to 0.1% for a 10,000 MU delivery translates to a reduction
from 100 to 10cGy in reference calibration condition. This
reduction in normal brain dose could be meaningful for re-
irradiation, as patients sometimes go through multiple sessions
of SRS to manage their brain metastases. For all HDMLC plans
in this study the jaw-tracking technique was enabled during
optimization. It has been shown that enabling jaw tracking, in
part, helps with reducing low dose spillage to the normal brain
tissues (19). If the jaw tracking technique is not available, it is
expected that the normal brain tissue receiving low dose (e.g.,
V3Gy) will further increase for HDMLC plans.
It should be emphasized again that this is strictly a
planning study to compare the achievable SRS plan quality
that this newly introduced MLC design is capable of, and
does not fully warrant the use of Halcyon for SRS treatment
even if the dosimetry is acceptable. Other factors, such as
delivery accuracy as a result of small fields and the imaging
system’s coincidence with the treatment beam system, need
to be well characterized before implementing this technique
on Halcyon. To ensure accurate treatment delivery of planned
dose, long term mechanical stability of the Halcyon system
will also need to be well characterized. Such characterization
should include Winston-Lutz or similar tests, MLC positioning
accuracy as a function of gantry angle for both layers, and
IGRT system performance. In addition, the omission of the
ability to perform 6D couch correction will require a 6D
adjustable mask or frame system to be used to perform
rotational corrections around pitch, roll, and yaw axes.
This is particularly important for multi-target treatment, as
targets away from isocenter are very sensitive to residual
rotational mismatches between the planned and treatment
positions.
Nevertheless, the data presented in this study show the great
potential of this dual-layer stacked and staggered MLC design,
despite the current limitation on non-coplanar delivery. The
conformity performance for targets> 1cm, coupled with reduced
leakage, are likely to translate into additional benefit to other
disease site applications where non-coplanar beam arrangements
are not typically used.
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CONCLUSION
A new dual-layer stacked and staggered MLC design
implemented in the Halcyon treatment delivery system has
been evaluated for the performance on single-isocenter multi-
target cranial treatment. Compared to clinical non-coplanar
dynamic conformal arc (DCA) plans, the system was found
to have comparable CI for targets >1 cm in diameter but
inferior GI, likely due to the limitation that only coplanar beam
arrangements can be used. V12Gy generated by Halcyon in a
coplanar setting was found to be similar to clinical non-coplanar
DCA plans. Reduced low dose spillage (V3Gy) was observed
for Halcyon plans compared to Truebeam plans, likely as a
result of reduced leakage in the new dual-layer MLC. Overall,
the new MLC showed great potential in conforming to a small
target while improving normal tissue blocking during high MU
treatment, but its advantage is limited due to the current machine
design which does not allow non-coplanar arcs. Planning quality
using the current HalcyonTM design is clinically acceptable for
treatments of multiple targets with diameter >1 cm. However,
for targets with diameter <1 cm, a unit with HDMLC and ability
to treat with non-coplanar fields appears superior to the current
Halcyon design. Future hardware and software developments
are needed to extend the capability of Halcyon to treat lesions
smaller than 1 cm.
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